Temporal Variability of Urinary Phthalate Metabolite Levels in Men of Reproductive Age by Hauser, Russ et al.
1734 VOLUME 112 | NUMBER 17 | December 2004 • Environmental Health Perspectives
Research | Article
Phthalates, diesters of phthalic acid, are a family
of multifunctional chemicals that are widely
used in personal and consumer products.
Phthalates are used to hold color and scent in
consumer and personal care products (Koo et
al. 2002); as solvents in paints, glue, insect
repellents, lubricants, and adhesives [Agency
for Toxic Substances and Disease Registry
(ATSDR 2001]; and to soften a wide range of
plastics (Bradbury 1996), including polyvinyl
chloride (PVC) used in the manufacture of
medical products such as blood, intravenous,
and dialysate bags and tubing (Nassberger et
al. 1987). Diethyl phthalate (DEP), di-n-butyl
phthalate (DBP), and butyl benzyl phthalate
(BBzP) are principally used in personal care
products, such as body lotions, gels, shampoos,
and deodorants (ATSDR 1995, 2001). They
also have U.S. Food and Drug Administration
approval for uses in food packaging and pro-
cessing materials that are in contact with food,
and as a result they have been found in food
(Castle et al. 1990; Page and Lacroix 1995).
DBP, BBzP, and di-(2-ethylhexyl) phthalate
are also used in residential building materials
such as floorings, paints, carpet backings,
adhesives, and wallpaper, and in PVC prod-
ucts such as auto parts and interiors (ATSDR
2001, 2002). Although the volatility of phtha-
lates is relatively low, studies have shown that
phthalates are present in residential indoor air
(Jaakkoala et al. 1999; Rudel et al. 2003).
The ubiquitous use of phthalates results
in human exposure via dietary ingestion of
foods (such as milk, butter, and meats), der-
mal absorption of low-molecular-weight
phthalates (e.g., DEP, DBP, BBzP), inhala-
tion of the more volatile phthalates, and par-
enteral exposure from medical devices
containing phthalates (ATSDR 1995, 2001,
2002). Recently, researchers at the Centers
for Disease Control and Prevention (CDC)
developed analytical methods for the quanti-
tative detection of phthalate metabolites in
urine (Blount et al. 2000). Phthalate
monoester metabolites were measured
because of potential sample contamination
from the parent diesters and because the
metabolites are considered the biologically
active toxicant (Li et al. 1998; Peck and Albro
1982: Sjoberg et al. 1986). The use of phtha-
late metabolites in urine as biomarkers of
exposure now allows researchers to accurately
measure human exposure to phthalates.
These biomarkers represent an integrative
measure of phthalate exposure from multiple
sources and pathways. Recently, four phtha-
late metabolites—monoethyl phthalate
(MEP), mono-(2-ethylhexyl) phthalate
(MEHP), monobutyl phthalate (MBP), and
monobenzyl phthalate (MBzP)—were found
in the urine samples of > 75% of approxi-
mately 2,550 participants of the National
Health Nutrition and Examination Survey
(NHANES) 1999–2000 (CDC 2003; Silva
et al. 2004).
Because humans and other mammals
rapidly metabolize phthalate diesters to their
respective monoesters, which in turn may be
further metabolized, phthalates do not bio-
accumulate (ATSDR 1995, 2001, 2002; Peck
and Albro 1982). Because biologic half-lives
of phthalates are on the order of hours, uri-
nary metabolite levels reflect exposures that
most likely occurred ≤ 1 day preceding the
collection of the urine specimen. However,
because most health end points of interest are
likely associated with exposures over time
intervals longer than a few days, information
on the temporal variability of urinary levels of
phthalate metabolites is needed to optimize
the design of exposure assessment in epidemi-
ologic studies. Currently there are limited
published data on the temporal variability of
urinary phthalate monoester metabolite con-
centrations. A recent study documented good
reproducibility of urinary phthalate monoester
levels in two first-morning urine specimens
collected for 2 consecutive days; day-to-day
intraclass correlation coefficients (ICCs)
ranged from 0.5 to 0.8 (Hoppin et al. 2002).
Time intervals beyond a couple of days were
not explored.
Variability in an individual’s exposure to
phthalates can result from changes in the use
of personal care products, diet, or daily activity
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Phthalates are a family of multifunctional chemicals widely used in personal care and other con-
sumer products. The ubiquitous use of phthalates results in human exposure through multiple
sources and routes, including dietary ingestion, dermal absorption, inhalation, and parenteral
exposure from medical devices containing phthalates. We explored the temporal variability over
3 months in urinary phthalate metabolite levels among 11 men who collected up to nine urine
samples each during this time period. Eight phthalate metabolites were measured by solid-phase
extraction–high-performance liquid chromatography–tandem mass spectrometry. Statistical analy-
ses were performed to determine the between- and within-subject variance apportionment, and
the sensitivity and speciﬁcity of a single urine sample to classify a subject’s 3-month average expo-
sure. Five of the eight phthalates were frequently detected. Monoethyl phthalate (MEP) was
detected in 100% of samples; monobutyl phthalate, monobenzyl phthalate, mono-2-ethylhexyl
phthalate (MEHP), and monomethyl phthalate were detected in > 90% of samples. Although we
found both substantial day-to-day and month-to-month variability in each individual’s urinary
phthalate metabolite levels, a single urine sample was moderately predictive of each subject’s expo-
sure over 3 months. The sensitivities ranged from 0.56 to 0.74. Both the degree of between- and
within-subject variance and the predictive ability of a single urine sample differed among phtha-
late metabolites. In particular, a single urine sample was most predictive for MEP and least predic-
tive for MEHP. These results suggest that the most efficient exposure assessment strategy for a
particular study may depend on the phthalates of interest. Key words: biomarkers, human, phtha-
lates, reliability, urine. Environ Health Perspect 112:1734–1740 (2004). doi:10.1289/ehp.7212
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environments (i.e., residential, workplace, or
other) with ambient phthalate levels.
Therefore, characterizing an individual’s
phthalate exposure is complex, and exposure
may vary considerably over short time peri-
ods, such as days. Although phthalate bio-
markers in urine are available to accurately
measure a person’s exposure at a single point
in time, determining exposure over time
intervals of weeks or months will require mul-
tiple measurements of phthalate metabolites.
Therefore, the present study was designed to
explore the temporal variability in urinary
phthalate metabolite levels. Our design
allowed us to determine between- and within-
subject variability in urinary phthalate
metabolite levels, as well as apportion the
within-person variability into monthly and
daily variances. We also explored the sensitiv-
ity of a single urine measurement to predict
an individual’s 3-month average exposure.
This information can be used for designing
exposure assessment strategies for epidemio-
logic studies and to adjust for measurement
error in phthalate exposure.
Materials and Methods
Eleven men from our ongoing study of the
relationship between environmental agents
and male reproductive health agreed to
participate in the phthalate variability study.
Participant recruitment into the environmental
agents and male reproductive health study has
been previously described (Hauser et al. 2003).
Brieﬂy, men who were the partner in couples
seeking fertility evaluation for inability to
conceive were recruited to participate. The
study site was the Massachusetts General
Hospital (MGH) Andrology Laboratory, so
most men resided in the New England area.
At the clinic visit, each man was asked to pro-
duce a single semen sample and to collect a
single spot urine sample.
For each of the 11 men in the phthalate
temporal variability study, up to nine addi-
tional spot urine samples were collected dur-
ing three cycles over a 92-day period. Ten of
these 11 men each contributed a total of
10 urine samples (nine for the variability
study and one for the male reproductive
study), whereas one of the men provided a
total of seven samples (including six for the
variability study). Nested within each of the
three cycles were three urine samples, col-
lected on the ﬁrst 3 consecutive days of each
cycle. The ﬁrst cycle began upon enrollment
into the phthalate temporal variability study,
and urine samples were collected on days 0, 1,
and 2. Cycles 2 and 3 began 30 days and
90 days after cycle 1, respectively. Therefore,
the nine urine samples were collected on days
0, 1, and 2 (cycle 1); days 30, 31, and 32
(cycle 2); and days 90, 91, and 92 (cycle 3).
All the urine samples were collected in a
sterile specimen cup. The urine sample on
day 0 was collected at the MGH Andrology
laboratory. All other samples were collected
at the subject’s home and frozen before
overnight shipment to the Harvard School of
Public Health (HSPH) on blue ice. All urine
samples were then shipped frozen on dry ice
from HSPH to CDC. Eight phthalate
monoesters—MBzP, MBP, MEP, MEHP,
monomethyl phthalate (MMP), mono-n-
octyl phthalate (MOP), mono-3-methyl-5-
dimethylhexyl phthalate (MINP), and
monocyclohexyl phthalate (MCHP)—were
measured in each spot urine sample using an
analytical approach developed at the CDC
(Silva et al. 2003). Brieﬂy, the determination
of phthalate metabolites in urine involved
enzymatic deconjugation of the glucuroni-
dated metabolites, solid-phase extraction,
separation with high-performance liquid
chromatography, and detection by tandem
mass spectrometry. Detection limits were in
the low micrograms per liter range. Reagent
blanks and 13C4-labeled internal standards
were used along with conjugated internal
standards to increase the precision of the
measurements. One method blank, two qual-
ity control samples (human urine spiked with
phthalates), and two sets of standards were
analyzed along with every 21 unknown urine
samples. Analysts at the CDC were blind to
all information concerning subjects.
Several methods adjust for urine volume
(Boeniger et al. 1993; Teass et al. 1998).
Although creatinine is a frequently used
form of adjustment, if a compound is
excreted primarily by tubular secretion it is
not appropriate to adjust for creatinine level
(Teass et al. 1998). Although the methods of
excretion of the phthalate monoesters meas-
ured in this study are unknown, terephthalic
acid was found to be actively secreted by
renal tubules and actively reabsorbed by the
kidney (Tremaine and Quebbemann 1985).
Furthermore, because organic compounds
that are glucuronidated in the liver, like the
phthalates, are eliminated by active tubular
secretion (Boeniger et al. 1993), creatinine
adjustment may not be appropriate for
phthalates. Additionally, creatinine levels
may be confounded by muscularity, physical
activity, urine flow, time of day, diet, and
disease states (Boeniger et al. 1993; Teass et
al. 1998). For these reasons, speciﬁc gravity,
rather than creatinine, was used to normalize
phthalate levels.
Urinary phthalate levels were normalized
for dilution by speciﬁc gravity adjustment using
the formula Pc = P × [(1.024 – 1)/(SG – 1)],
where Pc is the specific-gravity–corrected
phthalate concentration (micrograms per liter),
P is the observed phthalate concentration
(micrograms per liter), and SG is the specific
gravity of the urine sample (Boeniger et al.
1993; Teass et al. 1998). Speciﬁc gravity was
measured using a handheld refractometer
(National Instrument Company, Inc.,
Baltimore, MD), which was calibrated with
deionized water before each measurement.
Statistical analyses. We performed the
statistical analyses using the Statistical
Analysis Software (SAS), version 8.1 (SAS
Institute, Cary, NC). Both unadjusted and
specific-gravity–adjusted values were used.
For values below the limit of detection
(LOD), corresponding to 1.2 (MEP), 0.94
(MBP), 0.47 (MBzP), 0.86 (MEHP), 0.70
(MMP), 0.77 (MOP), 0.79 (MINP), and
0.93 µg/L (MCHP), we used an imputed
value equal to one-half the LOD.
We constructed graphs to compare
metabolite levels within and between subjects,
and calculated Spearman correlation coeffi-
cients to investigate correlations between sam-
ples collected at different time points.
To assess between- and within-person
variability of metabolite levels, we calculated
ICCs for each metabolite based on output
from a random effects model ﬁt using PROC
MIXED (Rosner 1999). ICC, deﬁned as the
ratio of between-person variance to total vari-
ance, is a measure of reliability of repeated
measures over time. ICC ranges from 0 to 1,
with values near 1 indicating high reliability
and values near 0 indicating poor reliability.
ICC can also be used in an internal validity
study to account for measurement error in
epidemiology effect estimates (Carroll et al.
1995; Rosner et al. 1992).
To apportion variances among nested com-
ponents, we fit a hierarchical model (using
PROC MIXED). For a more robust estimate of
between-subject variability, we used the results
of the single urine samples collected from all
369 men enrolled so far in the ongoing envi-
ronmental agents and male reproductive health
study in the variance apportionment analysis.
Because the 11 men in this variability study
were also enrolled in the male reproductive
health study, their single urine sample collected
for the reproductive study contributed addi-
tional information on variability. Within-sub-
ject variance was further apportioned into
cycle-to-cycle variance and day-to-day variance
(Box et al. 1978). Day-to-day variance was
deﬁned as the variance in phthalate metabolite
levels between samples 1 or 2 days apart,
regardless of whether they were collected in
cycle 1, 2, or 3. Cycle-to-cycle variance was
deﬁned as the variance between the three cycles
minus the day-to-day variances within the
cycles. Because day is nested within cycle, the
cycle-to-cycle variance uses information from
the three nested daily samples in cycles 1, 2,
and 3.
Although ICC is an indicator of reliability
for continuous measures, it does not measure
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may occur if exposure is categorized into ter-
tiles of low, medium, and high exposure. To
explore categorical exposure misclassiﬁcation,
we performed sensitivity and speciﬁcity analy-
ses and surrogate category analyses. In both
analyses, tertiles were created using the mean
of the nine repeat urine samples for each of
the 10 subjects in the variability study. The
subject with only six repeat urine samples was
not included in these analyses because he did
not have complete data. Tertiles based on the
369 single urine samples from subjects in the
male reproductive health study produced an
unbalanced and unstable design because some
of these tertiles contained zero subjects from
the variability study. This led to nonidentiﬁ-
able results for that tertile. Therefore, analyses
using tertiles based on the 369 single urine
samples are not presented.
In the surrogate category analysis, we cal-
culated actual values for surrogate categories
to show the quantitative differences in phtha-
late metabolite levels that correspond to the
relative categories defined by a single urine
sample from the 10 variability subjects
(Willett 1998). We grouped variability sub-
jects ﬁrst into tertiles by treating each of the
nine repeat urine samples as a single spot
urine sample (i.e., the surrogate method). For
instance, for each of the nine repeat urine
samples, the 10 subjects were categorized into
high, medium, or low tertiles. The “true
value” for these same subjects based on their
3-month average phthalate metabolite levels
(using all the nine replicate samples) was then
assigned to the tertiles defined by the single
(surrogate) sample. Each of the nine samples
was used as the surrogate sample in separate
calculations to check for consistency. Each
subject’s 10th sample from the male repro-
ductive health study was not used in this
analysis because this sample could have been
collected up to 12 months earlier.
We also evaluated sensitivity and speci-
ﬁcity of a single urine sample as a predictor of
high and low tertiles of 3-month average
phthalate metabolite levels by comparing the
distribution of predicted and observed levels
for agreement. For observed or “true” expo-
sure, we calculated 3-month average metabo-
lite levels (using all the nine replicate samples)
for each subject and divided the 10 subjects
into tertiles. The distribution of 96 individual
samples (10 subjects providing nine replicate
samples, one subject providing six) was then
also divided into tertiles, with each sample
representing a predicted value based on a sin-
gle spot urine sample. For each sample time
(days 0–92), agreement between predicted
and observed “true” tertile categorization was
scored across all subjects, resulting in nine
separate contingency tables. All nine tables
were then combined into a single table, where
overall sensitivity and specificity were calcu-
lated (Peck et al. 2003). The same method was
used to assess the sensitivity and speciﬁcity if
two samples, and then additionally if three
samples were taken for each subject at least one
cycle apart within a 92-day time period. When
evaluating the sensitivity of two and three sam-
ples, all possible combinations of sample pair-
ings from the nine repeated samples, excluding
samples from the same cycle, were used in the
analysis. The goal was to simulate and compare
the ability of exposure assessments that involve
one, two, or three urine samples to predict a
subject’s “true” 3-month average exposure ter-
tile classiﬁcation.
Results
We measured eight phthalate metabolites in
urine. However, because > 75% of the sam-
ples had nondetectable levels of MCHP,
MOP, and MINP, the results for these three
metabolites were not informative and were
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Figure 1. Nine repeated urine samples collected from 10 men over a 3-month period: MEHP.
(A) Unadjusted. (B) Speciﬁc-gravity adjusted.
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Figure 2. Nine repeated urine samples collected from 10 men over a 3-month period: MBzP.
(A) Unadjusted. (B) Speciﬁc-gravity adjusted.
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Figure 3. Nine repeated urine samples collected from 10 men over a 3-month period: MEP. (A) Unadjusted.
(B) Speciﬁc-gravity adjusted.
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Table 1. Distribution of phthalate metabolite levels (µg/L) measured in a single spot urine sample from 369 men.
Phthalate Geometric Selected percentiles
metabolite mean 10th 25th 50th 75th 90th 95th
Unadjusted
MEHP 5.7 0.5 1.9 5.2 17.2 63.6 110
MBzP 5.6 1.1 2.4 6.0 13.7 25.3 34.7
MEP 149 22.7 46.1 128 444 1,144 1,879
MBP 13.3 2.9 7.0 13.6 29.3 50.4 73.1
MMP 3.8 0.4 1.7 4.4 9.6 21.5 29.9
Speciﬁc-gravity adjusted
MEHP 6.8 0.8 2.4 6.5 19.5 64.5 120
MBzP 6.6 1.8 3.8 7.2 14.0 22.8 36.2
MEP 175 30.7 58.7 153 495 1,145 1,897
MBP 15.8 4.8 9.8 16 29.2 45.9 66.7
MMP 4.5 0.6 2.2 4.9 11.7 22.4 30.4not included in the analyses. MEP was
detected in 100% of samples, whereas MBP,
MBzP, MEHP, and MMP were detected in >
90% of samples.
Unadjusted and speciﬁc-gravity–adjusted
median concentrations of MEP, MBP,
MBzP, MEHP, and MMP from the 369 men
who provided a single urine sample for the
environmental agents and male reproductive
health study are presented in Table 1. Of
these 369 men, 11 also participated in the
variability study. Ten of the 11 men provided
nine urine samples collected over 92 days,
whereas 1 man collected six urine samples
over 32 days only. In Figures 1–5, the unad-
justed (Figures 1A–5A) and specific-
gravity–adjusted (Figures 1B–5B) urinary
phthalate metabolite concentrations are plot-
ted by day for each subject (the one subject
with only six urine samples was not plotted).
Even after dilution adjustment, there was still
substantial variability in phthalate metabolite
concentrations over time. MEHP concentra-
tions showed large within-subject variability,
whereas MEP showed less within-subject
variability.
Spearman correlation coefficients con-
ﬁrmed that urine samples taken closer together
in time (days apart) were more strongly corre-
lated than those collected months apart. The
between- and within-subject variance appor-
tionments for specific-gravity–adjusted 
phthalate levels are shown in Table 2. Within-
subject variance was then apportioned into
cycle-to-cycle and day-to-day variance. 
As expected, the standard errors of the
between-subject variance component estimates
remained the same or were reduced when the
single samples from the 358 men participants
in the environmental agents and male repro-
ductive health study were included in the
analysis. The single urine samples contributed
more information on between-subject than on
within-subject variability. The between-subject
variance estimates increased for all phthalate
monoesters except for MMP and MEP.
Between-subject variances ranged from 27.4%
for MMP to 71.3% for MBP; therefore, ICC
ranged from 0.27 for MMP to 0.71 for MBP.
Of the total subject variance among the
369 subjects, the day-to-day variance com-
ponent ranged from 27.2% (MBP) to
58.1% (MMP), whereas the cycle-to-cycle
variances ranged from 1.5% (MBP) to
16.3% (MEP). Cycle-to-cycle variance is the
within-subject variance remaining after day-
to-day variance is calculated using the repli-
cate samples nested within each of the three
cycles. These results suggest that, after
accounting for day-to-day variance, there is
little additional cycle-to-cycle variance.
Therefore, if we were to collect only two
urine samples a day apart, we would account
for 83.7–98.5%, depending on the phthalate
monoester, of the total subject variance,
which is composed of between- and within-
subject variance. Likewise, if we collected
two urine samples 1 month apart we would
account for both cycle-to-cycle and day-to-
day variability, or 100% of the within-sub-
ject variance.
To determine the predictive ability of a
single urine sample to correctly categorize a
subject’s exposure into high, medium, or low
tertiles, we calculated actual values (mean and
geometric mean values) for surrogate cate-
gories. The results are presented in Table 3
(only the 10 subjects who provided nine urine
samples each were used in this analysis).
Overall, the results suggest that a single spot
urine sample was predictive of the 3-month
average exposure because there were monoto-
nic increasing geometric means across tertiles.
For instance, for MBP, when a single sample
on day 0 was used to group subjects into low-,
medium-, and high-exposure groups, the
“true” geometric mean MBP levels increased
from 12.7 µg/L in the group designated as low
Article | Variability of urinary phthalates
Environmental Health Perspectives • VOLUME 112 | NUMBER 17 | December 2004 1737
Figure 4. Nine repeated urine samples collected from 10 men over a 3-month period: MBP. (A) Unadjusted.
(B) Speciﬁc-gravity adjusted.
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Figure 5. Nine repeated urine samples collected from 10 men over a 3-month period: MMP.
(A) Unadjusted. (B) Speciﬁc-gravity adjusted.
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Table 2. Variance apportionment for speciﬁc-gravity–adjusted phthalate levels in urine.
Variability subjects only (N = 11, n = 96) All subjectsa (N = 369, n = 465)
Percent of total Percent of total
Variance estimate ± SE variance Variance estimate ± SE variance
ln(MEHP)
Subjectb 0.49 ± 0.32 27.9 1.57 ± 0.31 54.3
Cyclec 0.30 ± 0.20 17.3 0.33 ± 0.21 11.4
Dayd 0.97 ± 0.17 54.7 0.99 ± 0.18 34.3
ln(MBzP)
Subject 0.47 ± 0.25 42.5 0.80 ± 0.14 55.1
Cycle 0.075 ± 0.086 6.9 0.083 ± 0.09 5.7
Day 0.54 ± 0.096 50.5 0.57 ± 0.10 39.2
ln(MEP)
Subject 1.08 ± 0.59 46.2 0.87 ± 0.19 42.9
Cycle 0.33 ± 0.20 14.5 0.33 ± 0.16 16.3
Day 0.89 ± 0.16 39.3 0.83 ± 0.13 40.9
ln(MBP)
Subject 0.14 ± 0.085 29.0 0.84 ± 0.10 71.3
Cycle 0.025 ± 0.046 5.0 0.018 ± 0.041 1.5
Day 0.33 ± 0.058 66.0 0.32 ± 0.059 27.2
ln(MMP)
Subject 1.11 ± 0.55 51.7 0.51 ± 0.21 27.4
Cycle 0.011 ± 0.12 0.5 0.27 ± 0.25 14.5
Day 1.03 ± 0.18 47.8 1.08 ± 0.19 58.1
Abbreviations: N, number of subjects; n, number of samples. 
aIncludes 10 variability subjects who provided 10 samples each, 1 subject who provided 7 samples, plus 358 subjects who
provided a single sample. bBetween-subject variance. cVariance between three cycles after accounting for nested day-to-
day variance. dVariance between 3 consecutive days within a cycle.exposure, to 22.8 µg/L in the medium-
exposure group, to 28.3 µg/L in the high-
exposure group. Although single spot urine
samples were generally predictive, there were
differences in the predictive ability of a single
urine sample for different phthalate mono-
esters. A single urine sample was least predic-
tive for MEHP, where only five of the nine
spot urine samples produced a monotonic
increasing geometric mean. In contrast, eight
of the nine spot urine samples produced
monotonic increasing geometric means for
MBzP, MBP, MEP, and MMP. As expected,
MEP, with the widest range in exposure levels,
showed the largest difference in geometric
means between low-, medium-, and high-
exposure categories.
For a more quantitative assessment of how
well a single urine sample predicts a subject’s
exposure category based on 3-month average
metabolite levels, we conducted sensitivity and
speciﬁcity analyses, using only the results from
the 10 subjects who provided nine urine sam-
ples each (Table 4). The proportion of men
who truly had the highest 3-month average
exposure (top 33%) that would be identiﬁed as
such using single urine samples anytime
throughout that 3-month period (i.e., sensitiv-
ity) ranged from 0.56 for MEHP to 0.74 for
MMP. The proportion of men with truly com-
paratively low exposure (tertiles 2 and 3) that
were classiﬁed correctly (i.e., speciﬁcity) ranged
from 0.83 for MEHP to 0.90 for MMP.
Sensitivity analyses for one, two, or three urine
samples are presented in Table 4. When two
samples were collected 1–3 months apart, there
were small increases in sensitivity and speci-
ficity, especially evident for MEHP. When
three urine samples were collected, each 1–3
months apart, sensitivity moderately increased
for MEHP and MMP, with slight increases for
the other monoesters. In contrast, when three
urine samples were collected on 3 consecutive
days, sensitivity for MEHP, MBzP, MBP, and
MMP did not increase. However, sensitivity
did increase for MEP.
We also performed all analyses described
above using unadjusted phthalate levels (data
not shown). Overall, variance apportionment
and sensitivity analyses were very similar to
the specific-gravity–adjusted results shown
above. The surrogate exposure category
method differed slightly with less consistent
dose–response categories found for the unad-
justed phthalate metabolite levels.
Discussion
Although the present study found substantial
within-subject variability in urinary phthalate
metabolite levels, the sensitivity of a single
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Table 3. Values for surrogate exposure categories comparing a single urine sample with 3-month average
levels based on nine replicates from 10 men.
Mean (µg/L) Geometric mean (µg/L)
Surrogate Low Medium High Low Medium High
MEHP
Day 0 19.9 28.9 44.7 9.3 11.5 18.3
Day 1 9.5 55.7 19.4 5.1 26.3 11.0
Day 2 18.8 26.2 49.3 7.1 11.1 25.2
Day 30 5.6 44.9 37.6 4.4 24.3 14.2
Day 31 5.6 43.8 39.0 4.4 20.1 18.4
Day 32 23.6 23.2 48.6 11.2 9.2 20.5
Day 90 10.0 29.7 53.5 5.0 12.7 29.9
Day 91 9.5 30.1 53.5 5.1 14.3 24.8
Day 92 10.2 31.1 51.5 6.1 11.7 27.5
MBzP
Day 0 4.9 11.2 14.3 3.1 7.5 13.2
Day 1 6.6 9.3 15.2 2.9 7.8 13.3
Day 2 7.8 9.2 14.0 4.3 6.0 12.8
Day 30 6.3 11.2 12.8 3.9 8.5 8.9
Day 31 6.6 10.1 14.0 2.9 8.0 12.8
Day 32 7.2 10.1 13.4 3.5 7.5 11.9
Day 90 8.3 11.1 11.0 4.2 7.8 9.2
Day 91 8.0 9.9 12.9 3.7 7.8 10.6
Day 92 7.2 9.9 13.7 3.5 7.8 11.3
MEP
Day 0 73.2 158.4 172 28.9 46.8 94.4
Day 1 26.6 199.6 163 15.8 98.3 64.1
Day 2 30.2 113 276 6.2 70.2 97.8
Day 30 146 92.8 186 24.4 39.7 139
Day 31 26.6 104 291 15.8 53.1 146
Day 32 26.6 182 186 15.8 55.0 139
Day 90 30.2 158 216 16.2 50.2 153
Day 91 33.4 155 216 16.0 50.7 153
Day 92 63.9 132 216 20.3 42.4 153
MBP
Day 0 16.3 30 30.5 12.7 22.8 28.3
Day 1 16.7 24.9 37.3 13.1 21.6 29.3
Day 2 16.7 26.3 35.5 13.1 20.5 31.4
Day 30 18.0 23.4 38.1 13.5 18.6 34.7
Day 31 16.3 27.7 34.0 12.7 22.7 28.5
Day 32 16.7 27.7 33.6 13.1 22.7 27.6
Day 90 26.4 24.4 28.4 19.8 21.6 19.4
Day 91 21.7 22.0 36.3 14.4 18.7 32.3
Day 92 21.3 26.6 30.5 13.9 21.3 28.3
MMP
Day 0 4.2 7.9 30.2 2.0 5.6 23.2
Day 1 4.0 9.4 28.3 2.4 5.2 21.3
Day 2 5.0 7.3 30.2 4.1 3.3 23.2
Day 30 3.9 8.1 30.2 2.1 5.3 23.2
Day 31 4.3 9.2 28.3 2.5 5.0 21.3
Day 32 4.9 11.5 24.8 3.3 5.7 13.7
Day 90 4.2 12.4 24.3 2.0 6.2 19.9
Day 91 4.3 12.3 24.3 2.5 5.3 19.9
Day 92 4.0 12.5 24.3 2.2 5.8 19.9
Only samples from the 10 subjects who provided nine urine samples each were used in this analysis.
Table 4. Sensitivity and specificity for predicting men with the highest 3-month average phthalate levels (top 33%) with one, two, or three urine samples
(n = 10 men, 90 samples).
MEHP MBzP MEP MBP MMP
No. of samples Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity
One sample 0.56 0.83 0.63 0.84 0.63 (0.67)a 0.87 (0.86) 0.67 0.87 0.74 0.90
Two samples (at least 1 month apart) 0.63 0.84 0.65 0.85 0.69 (0.78) 0.88 (0.90) 0.65 0.85 0.81 0.92
Three samples (at least 1 month apart) 0.73 0.88 0.69 0.87 0.68 (0.70) 0.88 (0.87) 0.68 0.86 0.90 0.96
Three samples (3 consecutive days) 0.56 0.81 0.67 0.86 0.78 (0.67) 0.90 (0.90) 0.67 0.86 0.78 0.90
Only samples from the 10 subjects who provided nine urine samples each were used in this analysis.
aValues in parentheses are sensitivity and speciﬁcity using geometric mean ranks instead of arithmetic mean ranks for observed tertile classiﬁcation; for the other four phthalates these
values were identical.spot urine sample to predict 3-month average
phthalate exposure was moderate to high. As
expected, because phthalates are rapidly
metabolized and do not bioaccumulate, the
collection of additional urine samples
1–3 months apart improves the prediction of
a subject’s 3-month average exposure. The
levels of urinary metabolite levels found in
the present study were similar to reference
ranges measured in U.S. males for NHANES
1999–2000 (CDC 2003; Silva et al. 2004).
The predictive ability of a single urine
sample to determine a subject’s 3-month aver-
age exposure varied across phthalates. For
MEHP, a single urine sample was least pre-
dictive of the tertile categorization and had
the lowest sensitivity (Table 4). This implies
that in statistical analyses in which only a sin-
gle urine sample is available to categorize a
subject’s 3-month exposure to MEHP, there
is likely exposure measure misclassification
resulting in bias toward the null hypothesis
for exposure–response relationships. MEHP
has been associated with developmental
reproductive toxicity in laboratory studies
(Oishi 1986; Park et al. 2002; Sjoberg et al.
1986). However, in our previously published
study, we did not ﬁnd an association between
MEHP and semen parameters among adult
men (Duty et al. 2003). In contrast, we did
find associations of MBP and MBzP with
semen parameters. Although our study dif-
fered from the animal studies because we
measured adult and not gestational exposure,
our findings suggesting that a single urine
sample, used to categorize a subject’s expo-
sure, did not adequately measure 3-month
average exposure to MEHP. This may par-
tially explain our inability to detect associa-
tions between semen parameters with MEHP.
To improve upon our exposure classiﬁcation
of MEHP, we are currently collecting two
urine samples 1 month apart from all sub-
jects. This will allow us to use measurement
error correction methods to adjust for expo-
sure misclassification of phthalate exposure
(Carroll et al. 1995).
It is possible the calculated sensitivities
and speciﬁcities may be slightly overestimated
to a small degree because we included pre-
dicted values in the calculation of the
observed values. Therefore, the errors of 
predicted and observed values are not totally
independent, which can lead to an overesti-
mation of sensitivity and specificity (Willett
1998). Similarly, a portion of the increased
sensitivity and speciﬁcity observed when tak-
ing two or three samples per subject instead
of a single sample may be caused partly by the
increased dependence between the errors of
the predicted and observed values.
Apportioning the sources of variability in
urinary phthalate metabolite levels can be used
to design more valid and efficient exposure
assessments. As expected, the urinary phtha-
late metabolite concentrations in samples col-
lected close together in time, separated by
1–2 days, were more correlated than those in
samples collected farther apart in time, sepa-
rated by 1–3 months. Two samples collected a
month or more apart include variability in uri-
nary phthalate metabolite levels contributed to
both by day-to-day changes in exposure and
by monthly trends in phthalate exposure, such
as seasonal changes in diet, personal product
use, or activity patterns, as well as other
environmental or biologic factors.
For each health end point of interest in an
epidemiologic study, the relevant time win-
dow over which exposure is measured needs to
be defined. For acute responses after acute
exposures, a single urine sample may be ade-
quate to deﬁne phthalate exposure. However,
we are generally interested in health end
points that have exposure windows of months,
if not years. To this end, accurate exposure
assessment depends on a strategy whereby we
accurately measure exposure over these time
windows. The simplest approach is to collect
multiple urine samples from all subjects over
the time interval of interest. However, it is not
always feasible to collect multiple urine sam-
ples because of both cost constraints and limi-
tations imposed by the subject’s commitments
to multiple collections. Based on the results of
this phthalate variability study, for male
reproductive health end points, we recom-
mend collecting at least two urine samples
1–3 months apart. This will provide an esti-
mate of the within-person variability taking
into account both month-to-month and day-
to-day variance. Nevertheless, if the study
design only permitted collecting two samples
1–2 days apart, this, too, would provide a rea-
sonable estimate of within-subject variance
contributed to by day-to-day variance. After
collection of the replicate urine samples in
either sampling scheme, measurement error
models could then be used to adjust for mea-
surement error in exposure (Carroll et al.
1995). A discussion of this is beyond the
scope of this report.
In conclusion, although a single urine sam-
ple was moderately predictive of 3-month
exposure to phthalates, the predictive ability
varied across phthalate monoesters. A single
urine sample was more predictive for MEP and
less predictive for MEHP. The single sample
performed well in classifying a subject’s expo-
sure into tertiles, and the amount of nondiffer-
ential random exposure misclassification is
likely to be moderate or small for most phtha-
late metabolites of interest. The variance
apportionment analysis suggests that two urine
samples, the second collected 1–3 months after
the first sample, is the minimum number of
samples necessary to account for the within
subject day-to-day and cycle-to-cycle variability
in urinary phthalate metabolite levels. Because
the degree of between- and within-subject vari-
ance and thus the predictive ability of a single
urine sample differ among phthalate metabo-
lites, the most efficient exposure assessment
strategy for a particular study depends on the
phthalates of interest. The results from the pre-
sent study will be used in our ongoing environ-
mental agents and male reproductive health
study to correct for measurement error in the
effect estimates of exposure–response relation-
ships between phthalates and sperm function.
The findings from this variability study may
also be pertinent to other end points with rele-
vant exposure periods of several months.
However, if the study population is not adult
men of reproductive age, such as studies
involving children or pregnant women, we rec-
ommend that a variability study be conducted
to determine population-specific exposure
assessment strategies.
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Correction
The values in Tables 1 and 3 have been
rounded from those in the manuscript pub-
lished online to reflect laboratory sensitivi-
ties. In Table 2, for all subjects the SE for
ln(MBzP) day is 0.10, and that for percent
of total variance ln(MEP) day is 40.9. The
errors have been corrected here.